CNTG - Centogene and Pfizer expand collaboration agreement

Centogene N.V. (NASDAQ:CNTG), a German biotech focused on rare disorders, announced on Thursday that the company agreed to expand its data access and collaboration agreement with the U.S. pharma giant Pfizer (PFE). In 2019, the two companies signed an initial agreement to identify and validate genetic and biochemical targets for the potential development of new treatments for rare diseases. The newly established research project includes attempts “to validate rare genetic causes of neurodegenerative diseases as possible targets for specific diseases,” the company said. Existing patient samples of CENTOGENE’s Bio/Databank will form the basis to generate data for the initiative, which was identified by the company as a “new research phase” aimed at verifying earlier results. The expansion to the existing deal comes a few weeks after the company made Kim Stratton its permanent Chief Executive Officer.

For further details see:

Centogene and Pfizer expand collaboration agreement